文献速递膀胱癌与上尿路尿路上皮癌

DNA甲基化尿液生物标志物检测在上尿路尿路上皮癌诊断中的应用:单中心前瞻性临床试验结果

DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial.
PubMed 文献 · J Urol · 2022-05-12

这项单臂、盲法、前瞻性、单中心研究(2019年2月至2020年12月)纳入疑似上尿路尿路上皮癌(UTUC)拟行输尿管镜的患者,比较Bladder EpiCheck(EpiCheck)与尿细胞学在膀胱和上尿路样本中的诊断准确性。EpiCheck在上尿路样本中灵敏度/特异度/阴性预测值/阳性预测值分别为83%/79%/77%/84%,细胞学为59%/88%/61%/87%;高级别肿瘤灵敏度/阴性预测值为96%/97% vs 71%/86%。作者认为EpiCheck可能有助于减少不必要的输尿管镜,但其在UTUC中的临床实施需在多中心前瞻性随机试验中进一步研究。

要点

  • EpiCheck在上尿路样本中诊断高级别UTUC的灵敏度为96%、阴性预测值为97%。
  • EpiCheck指示45/80(56%)患者行输尿管镜,漏诊全部/高级别UTUC分别为17%/4%,9%为不必要的输尿管镜。
  • EpiCheck在UTUC中的临床实施需在多中心前瞻性随机试验中进一步研究。

核心结论

  • EpiCheck可能是减少不必要输尿管镜的重要工具,但其在UTUC中的临床实施需在多中心前瞻性随机试验中进一步研究。

研究设计与样本

  • 单臂、盲法、前瞻性、单中心研究(2019年2月至2020年12月),纳入所有因疑似UTUC拟行输尿管镜的患者。
  • 在输尿管镜前采集膀胱和上尿路样本,用于细胞学和EpiCheck检测,计算并比较EpiCheck在膀胱和上尿路样本中的准确性。

主要发现

  • EpiCheck在上尿路和膀胱样本中分别有83/86(97%)和73/75(97%)可出诊断结果,组织学阳性分别为47/83(57%)和42/73(58%)。
  • 上尿路样本中,EpiCheck灵敏度/特异度/阴性预测值/阳性预测值分别为83%/79%/77%/84%,细胞学为59%/88%/61%/87%。
  • 高级别肿瘤的上尿路样本灵敏度/阴性预测值:EpiCheck为96%/97%,细胞学为71%/86%。
  • EpiCheck指示45/80(56%)患者行输尿管镜,漏诊全部/高级别UTUC分别为17%/4%,9%为不必要的输尿管镜。
  • 膀胱样本中高级别肿瘤的灵敏度/阴性预测值:EpiCheck为71%/88%,细胞学为59%/87%。

关键数值与推荐

  • 上尿路样本EpiCheck灵敏度83%、特异度79%、阴性预测值77%、阳性预测值84%。
  • 上尿路样本细胞学灵敏度59%、特异度88%、阴性预测值61%、阳性预测值87%。
  • 高级别肿瘤上尿路样本EpiCheck灵敏度96%、阴性预测值97%,细胞学灵敏度71%、阴性预测值86%。
  • 膀胱样本高级别肿瘤EpiCheck灵敏度71%、阴性预测值88%,细胞学灵敏度59%、阴性预测值87%。

临床怎么用

  • 作者认为EpiCheck可能是减少不必要输尿管镜的重要工具。
  • 作者指出EpiCheck在UTUC中的临床实施需在多中心前瞻性随机试验中进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The correct risk categorization and staging of upper tract urothelial cancer (UTUC) is key for disease management. Computerized tomography urography and urinary cytology have limited accuracy for risk stratification of UTUC. Ureteroscopy may increase the risk of bladder cancer recurrence. Recently, Bladder EpiCheckTM (EpiCheck) showed a high accuracy in the detection of bladder cancer. The aim of the study is to investigate the diagnostic accuracy of EpiCheck in the clinical management of UTUC and to compare it with urinary cytology. MATERIALS AND METHODS: In this single-arm, blinded, prospective, single-center study (February 2019-December 2020), all patients who were candidates for ureteroscopy for suspicion of UTUC were included. Bladder and upper urinary tract (UUT) samples were collected before ureteroscopy to test for cytology and Epicheck. EpiCheck accuracy was calculated in bladder and UUT samples and compared to cytology. RESULTS: EpiCheck resulted diagnostic in 83/86 (97%) and 73/75 (97%) of UUT and bladder samples. Histology was positive in 47/83 (57%) and 42/73 (58%) cases, respectively. In UUT samples, EpiCheck yielded a sensitivity/specificity/ negative predictive value (NPV)/positive predictive value of 83%/79%/77%/84% vs 59%/88%/61%/87% of cytology. The sensitivity/NPV for high-grade tumors was 96%/97% for EpiCheck vs 71%/86% for cytology. EpiCheck indicated ureteroscopy in 45/80 (56%) patients, missing 17%/4% of all/high-grade UTUC with 9% of unnecessary ureteroscopy. In bladder samples, the sensitivity/NPV for high-grade tumors was 71%/88% for EpiCheck and 59%/87% for cytology. CONCLUSIONS: Epicheck may be an important tool to decrease the number of unnecessary ureteroscopy. The clinical implementation of EpiCheck in UTUC warrants further investigation in multicentric prospective randomized trials.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Territo A, Gallioli A, Diana P, et al. DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial. J Urol. 2022. PMID: 35549312. doi:10.1097/JU.0000000000002748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。